Answers are grounded in this paper and cite their sources.
Background and Objectives: Hidradenitis suppurativa (HS) is a heterogeneous inflammatory skin disease. Patients with similar disease severity may differ in clinical presentation and treatment response. This narrative review summarizes current evidence on clinical phenotypes, genetic factors and molecular endotypes in HS, with a focus on their potential role in precision medicine. Materials and Methods: This narrative review discusses published studies on clinical phenotypes, anatomical distribution, genetic factors, molecular endotypes and treatment response in HS. Clinical and molecular findings were considered in relation to their potential relevance for individualized treatment. Results: Several clinical phenotypes have been proposed based on lesion morphology and anatomical distribution, but no standardized classification system has been established. Genetic studies indicate a heterogeneous genetic background, including rare variants affecting the γ-secretase complex and common genetic variants associated with HS susceptibility. Transcriptomic and single-cell studies have identified distinct molecular profiles in different HS lesions and have proposed several molecular subtypes and endotypes. Clinical characteristics have been associated with treatment response to selected therapies, including acitretin, secukinumab and adalimumab. Molecular features have also been associated with treatment response to adalimumab, brodalumab and risankizumab. However, most of these findings are based on small or exploratory studies and require further validation. Conclusions: Precision medicine in HS remains an emerging approach. Further prospective studies are needed to determine whether combining clinical, genetic and molecular information can improve treatment selection and patient outcomes.
No takes yet. Share an insight, caveat, or question.
Putek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: